Saltar al contenido
Merck

Saltar a

SML2287

Posaconazole

≥98% (HPLC), lanosterol 14α-demethylase inhibitor, powder

Sinónimos:

Posaconazole solution, 2,5-Anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-[[4-[4-[4-[1-[(1S,2S)-1-ethyl-2-hydroxypropyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]phenyl]-1-piperazinyl]phenoxy]methyl]-1-(1H-1,2,4-triazol-1-yl)-D-threo-pentitol, Sch 56592

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Cambiar Vistas
Tamaño de envaseSKUDisponibilidadPrecio
5 mg
Comprobar disponibilidad del carrito
$162.000
25 mg
Comprobar disponibilidad del carrito
$595.000

Acerca de este artículo

Fórmula empírica (notación de Hill):
C37H42F2N8O4
Número CAS:
Peso molecular:
700.78
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder

$162.000


Comprobar disponibilidad del carrito

Solicite una orden a granel
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle


Nombre del producto

Posaconazole, ≥98% (HPLC)

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D -24 to -32°, c = 1.0 in chloroform-d

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

SMILES string

Fc1c(ccc(c1)F)[C@@]3(OC[C@H](C3)COc4ccc(cc4)N5CCN(CC5)c6ccc(cc6)N7C=NN(C7=O)[C@H]([C@@H](O)C)CC)C[n]2ncnc2

InChI

1S/C37H42F2N8O4/c1-3-35(26(2)48)47-36(49)46(25-42-47)31-7-5-29(6-8-31)43-14-16-44(17-15-43)30-9-11-32(12-10-30)50-20-27-19-37(51-21-27,22-45-24-40-23-41-45)33-13-4-28(38)18-34(33)39/h4-13,18,23-27,35,48H,3,14-17,19-22H2,1-2H3/t26-,27+,35-,37-/m0/s1

InChI key

RAGOYPUPXAKGKH-XAKZXMRKSA-N

Application

Posaconazole has been used:
  • in antifungal susceptibility testing of Aspergillus terreus[1]
  • as a lanosterol 14α-demethylase (CYP51)-specific inhibitor to study its effects on membrane permeability in Candida albicans cells[2]
  • to study its effects on promastigotes[3]

Biochem/physiol Actions

Posaconazole is a highly potent broadspectrum antifungal agent against the yeast infection caused especially by Candida sp.[4][5] It blocks the growth of fungi by inhibiting the enzyme lanosterol 14α-demethylase (CYP51).[4] In contrast to other antifungal azoles, posaconazole has been reported not to induce the efflux pump mechanism. Posaconazole exhibits antichagasic effects against different strains of Trypanosoma cruzi causing Chagas disease.[6]

Comparar elementos similares

Ver comparación completa

Mostrar Diferencias

1 of 1

Este artículo
SML235732103SML1244
assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

-

assay

≥98% (HPLC)

form

powder

form

powder

form

-

form

powder

storage temp.

−20°C

storage temp.

2-8°C

storage temp.

-

storage temp.

−20°C

solubility

DMSO: 2 mg/mL, clear

solubility

DMSO: 2 mg/mL, clear

solubility

-

solubility

DMSO: 20 mg/mL, clear

color

white to beige

color

white to beige

color

-

color

white to beige

optical activity

[α]/D -24 to -32°, c = 1.0 in chloroform-d

optical activity

-

optical activity

-

optical activity

[α]/D -85 to -95°, c = 1 in chloroform


Still not finding the right product?

Explore all of our products under


Clase de almacenamiento

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos



Chiung-Kuang Chen et al.
PLoS neglected tropical diseases, 4(4), e651-e651 (2010-04-14)
Chagas Disease is the leading cause of heart failure in Latin America. Current drug therapy is limited by issues of both efficacy and severe side effects. Trypansoma cruzi, the protozoan agent of Chagas Disease, is closely related to two other
Israel Molina et al.
Current opinion in infectious diseases, 28(5), 397-407 (2015-07-24)
The current therapeutic scenario against Chagas disease has been recently updated with the use of the triazoles in clinical trials and several experimental assays (in-vitro and in-vivo models) which are bringing novel and promising evidence for the treatment of Chagas
Galina I Lepesheva et al.
The Journal of biological chemistry, 285(33), 25582-25590 (2010-06-10)
Trypanosoma cruzi causes Chagas disease (American trypanosomiasis), which threatens the lives of millions of people and remains incurable in its chronic stage. The antifungal drug posaconazole that blocks sterol biosynthesis in the parasite is the only compound entering clinical trials



Número de artículo de comercio global

SKUGTIN
SML2287-25MG04061835307159
SML2287-5MG04061835307166

Questions

Reviews

No rating value

Active Filters